dc.contributor.author |
Akpinar, S |
|
dc.contributor.author |
Dogu, MH |
|
dc.contributor.author |
Celik, S |
|
dc.contributor.author |
Ekinci, O |
|
dc.contributor.author |
Hindilerden, IY |
|
dc.contributor.author |
Dal, MS |
|
dc.contributor.author |
Davulcu, EA |
|
dc.contributor.author |
Tekinalp, A |
|
dc.contributor.author |
Hindilerden, F |
|
dc.contributor.author |
Ozcan, BG |
|
dc.contributor.author |
Hacibekiroglu, T |
|
dc.contributor.author |
Erkurt, MA |
|
dc.contributor.author |
Bagci, M |
|
dc.contributor.author |
Namdaroglu, S |
|
dc.contributor.author |
Korkmaz, G |
|
dc.contributor.author |
Bilgir, O |
|
dc.contributor.author |
Cagliyan, GA |
|
dc.contributor.author |
Ozturk, HBA |
|
dc.contributor.author |
Serin, I |
|
dc.contributor.author |
Tiryaki, TO |
|
dc.contributor.author |
Ozatli, D |
|
dc.contributor.author |
Korkmaz, S |
|
dc.contributor.author |
Ulas, T |
|
dc.contributor.author |
Eser, B |
|
dc.contributor.author |
Turgut, B |
|
dc.contributor.author |
Altuntas, F |
|
dc.date.accessioned |
2023-01-02T08:53:08Z |
|
dc.date.available |
2023-01-02T08:53:08Z |
|
dc.date.issued |
2022 |
|
dc.identifier.uri |
http://hdl.handle.net/11616/86955 |
|
dc.description.abstract |
We evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months, 146 patients (75%) achieved at least PR; 16 (8.7%) patients discontinued ibrutinib due to adverse events. The results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. |
|
dc.description.abstract |
Introduction/Background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL in real-world settings. Patients/Methods: A total of 200 relapsed/refractory CLL patients with a median age of 68 were included in this retrospective, multicenter, non-interventional study. Data of the study were captured from the patient charts of the par ticipating centers. Results: The median for lines of previous chemotherapy was 2 (1-6); 62 (31.8%) patients had del17p and/or p53 mutations (del17p+ /p53mut). Of the study group, 146 (75%) patients achieved at least PR, while 16 (8.7%) patients discontinued ibrutinib due to TEA. The most common drug-related adverse events were neutropenia (n: 31; 17.4%) and thrombocytopenia (n: 40; 22.3%), which were >= grade 3 in 9 (5%) and 5 (3.9%) patients, respectively. Pneumonia (n: 42; 23.7%) was the most common nonhematologic TEA. Atr ial fibrillation (n: 5; 2.8%) and bleeding (n: 11; 6.3%) were relatively rare dur ing the study period. Within a median follow-up period of 17 (1-74) months, 42 (21%) patients died. The estimated median OS of the study cohort was 52 months. Only the response to ibrutinib (CR/PR vs. SD/PD) was significantly associated with OS. Conclusion: Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. (C) 2021 Elsevier Inc. All rights reserved. |
|
dc.source |
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA |
|
dc.title |
The Real-World Experience With Single Agent Ibrutinib in |
|
dc.title |
Relapsed/Refractory CLL |
|